^
Association details:
| Biomarker: | GNAQ mutation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | tris DBA palladium (Tris DBA) (NLRP3 inhibitor, ARF6 inhibitor, GNAQ inhibitor, NMT-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
Excerpt:
...Tris DBA palladium was orally effective against GNAQ mutant melanoma in vivo.
DOI:
10.18632/oncotarget.27040
